Logistic regression was used to calculate odds ratios and 95% confidence intervals. The inclusion criteria were met by 3649 HCC cases, 743 ICC cases, and 195,953 comparison persons. Metabolic syndrome was significantly more common among persons who

developed HCC (37.1%) and ICC (29.7%) than the comparison group (17.1%, P < 0.0001). In adjusted multiple logistic regression analyses, metabolic syndrome remained significantly associated with increased risk of HCC (odds ratio = 2.13; 95% confidence interval = 1.96-2.31, P < 0.0001) and ICC (odds ratio = 1.56; 95% confidence interval = 1.32-1.83, P < 0.0001). Conclusion: Metabolic syndrome is a significant Daporinad purchase risk factor for development of HCC and ICC in the general U.S. population. (HEPATOLOGY 2011;) The incidences of both types of primary liver cancer, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), have increased in the United States.1, 2 Major risk factors for HCC in industrialized countries are chronic infection with hepatitis C virus (HCV), chronic infection with hepatitis B virus (HBV), and excessive alcohol consumption.3 The documented increase in HCV- and HBV-related HCC, however, does not fully explain the recent increase in HCC incidence, because 20%-50% of HCC cases remain idiopathic.3 ICC has been associated

with several diseases of the biliary tract selleck compound library or liver, such as primary sclerosing cholangitis, Caroli’s disease, cholelithiasis, HCV infection, liver fluke infestation, and inflammatory bowel disease.4 These factors account for only a small proportion of the attributable risk of ICC in the United States, because many ICC cases do not appear to be associated with any of the abovementioned risk factors.5 In recent years, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis

(NASH) have received increasing attention for their relationship with end-stage liver disease and HCC.6-11 NAFLD and NASH are clearly associated with Teicoplanin the metabolic syndrome, comprising a cluster of interrelated metabolic risk factors such as raised fasting glucose, central obesity, dyslipoproteinemia, and hypertension.12-15 In concert with the recent worldwide epidemic of obesity and metabolic syndrome,16-18 the incidence and prevalence of NAFLD has also increased. It is estimated that up to 37% of the population in industrialized countries exhibit NAFLD, turning it into the most frequent liver disease in these countries.13, 19, 20 The association between metabolic syndrome or NAFLD/NASH and HCC has been documented in case reports, case series, and longitudinal studies7, 8, 11, 21-24; however, larger population-based studies investigating the magnitude of this association in the United States are lacking.